IgA Serological Response for the Diagnosis of Mycobacterium abscessus Infections in Patients with Cystic Fibrosis.
ELISA
IgA
cystic fibrosis
non-tuberculous mycobacteria
serodiagnosis
serology
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
29 06 2022
29 06 2022
Historique:
pubmed:
19
5
2022
medline:
2
7
2022
entrez:
18
5
2022
Statut:
ppublish
Résumé
The immunoglobulin A (IgA) status of cystic fibrosis (CF) patients, presenting with or without a non-tuberculous mycobacterial (NTM) infection, has to date not been fully elucidated toward two antigenic preparations previously described. We have chosen to determine the clinical values of an IgA ELISA for the diagnosis of NTM and/or Mycobacterium abscessus infections in CF patients. One hundred and 73 sera from CF patients, comprising 33 patients with M. abscessus positive cultures, and 31 non-CF healthy controls were assessed. IgA levels were evaluated by indirect ELISAs using a surface antigenic extract named TLR2eF for TLR2 positive extract and a recombinant protein, the phospholipase C (rMAB_0555 or rPLC). These assays revealed a sensitivity of 52.6% (95% CI = 35.8% to 69%) and 42.1% (95% CI = 26.3% to 59.2%) using TLR2eF and rPLC, respectively, and respective specificities of 92.6% (95% CI = 87.5% to 96.1%) and 92% (95% CI = 86.7% to 95.7%) for samples culture positive for M. abscessus. Overall sensitivity and specificity of 66.7% and 85.4%, respectively, were calculated for IgA detection in M. abscessus-culture positive CF patients, when we combine the results of the two used antigens, thus demonstrating the efficiency in detection of positive cases for these two antigens with IgA isotype. CF patients with a positive culture for M. abscessus had the highest IgA titers against TLR2eF and rPLC. The diagnosis of NTM infections, including those due to M. abscessus, can be improved by the addition of an IgA serological assay, especially when cultures, for example, are negative. Based on these promising results, a serological follow-up of a larger number of patients should be performed to determine if the IgA response may be correlated with an active/acute infection state or a very recent infection.
Identifiants
pubmed: 35583329
doi: 10.1128/spectrum.00192-22
pmc: PMC9241595
doi:
Substances chimiques
Immunoglobulin A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0019222Références
J Infect Dis. 2021 Jul 15;224(2):218-228
pubmed: 33905505
J Clin Microbiol. 2009 Dec;47(12):4124-8
pubmed: 19846643
Biochem J. 1990 Oct 15;271(2):285-96
pubmed: 2241915
Jpn J Infect Dis. 2017 Sep 25;70(5):582-585
pubmed: 28367886
PLoS One. 2020 Nov 30;15(11):e0242598
pubmed: 33253290
Scand J Immunol. 2013 Sep;78(3):266-74
pubmed: 23713613
Clin Vaccine Immunol. 2010 Dec;17(12):1963-9
pubmed: 20962209
J Cyst Fibros. 2022 Mar;21(2):353-360
pubmed: 34511392
Mediators Inflamm. 2015;2015:364758
pubmed: 26347586
J Clin Microbiol. 1988 Nov;26(11):2313-8
pubmed: 2466869
Clin Diagn Lab Immunol. 2004 Jan;11(1):70-6
pubmed: 14715547
Oncotarget. 2017 Jun 6;8(23):37525-37537
pubmed: 28415587
Respir Investig. 2019 Sep;57(5):410-414
pubmed: 31085120
J Inflamm Res. 2021 Jun 14;14:2497-2506
pubmed: 34163208
Annu Rev Immunol. 2003;21:177-204
pubmed: 12524384
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):179-90
pubmed: 16510311
J Clin Microbiol. 2013 Aug;51(8):2747-9
pubmed: 23740728
Tuberculosis (Edinb). 2013 Mar;93(2):189-91
pubmed: 23140854
PLoS One. 2019 Jul 1;14(7):e0219255
pubmed: 31260500
Respir Res. 2020 Jun 16;21(1):153
pubmed: 32546152
Int J Mycobacteriol. 2020 Jan-Mar;9(1):76-82
pubmed: 32474493
Clin Infect Dis. 2002 Dec 1;35(11):1328-35
pubmed: 12439795
J Clin Tuberc Other Mycobact Dis. 2020 Sep 11;21:100189
pubmed: 32995571